다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

XBIT

XBiotech (XBIT)

XBiotech Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:XBIT

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/11	00:27	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XBIT	XBiotech Inc
2024/02/08	02:36	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:XBIT	XBiotech Inc
2024/02/08	02:01	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:XBIT	XBiotech Inc
2024/01/06	00:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XBIT	XBiotech Inc
2024/01/04	23:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XBIT	XBiotech Inc
2024/01/04	23:00	GlobeNewswire Inc.	XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	NASDAQ:XBIT	XBiotech Inc
2024/01/04	23:00	GlobeNewswire Inc.	XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	NASDAQ:XBIT	XBiotech Inc
2023/11/14	23:00	GlobeNewswire Inc.	Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis	NASDAQ:XBIT	XBiotech Inc
2023/11/10	04:41	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XBIT	XBiotech Inc
2023/09/26	22:00	GlobeNewswire Inc.	XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke	NASDAQ:XBIT	XBiotech Inc
2023/08/30	22:00	GlobeNewswire Inc.	XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	NASDAQ:XBIT	XBiotech Inc
2023/08/12	00:18	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XBIT	XBiotech Inc
2023/08/09	00:47	GlobeNewswire Inc.	XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial	NASDAQ:XBIT	XBiotech Inc
2023/06/26	21:48	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XBIT	XBiotech Inc
2023/06/26	21:46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XBIT	XBiotech Inc
2023/06/26	21:43	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XBIT	XBiotech Inc
2023/06/26	21:40	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XBIT	XBiotech Inc
2023/06/24	04:04	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XBIT	XBiotech Inc
2023/06/20	22:20	Edgar (US Regulatory)	Amended Tender Offer Statement by Issuer (sc To-i/a)	NASDAQ:XBIT	XBiotech Inc
2023/05/22	22:00	GlobeNewswire Inc.	FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients	NASDAQ:XBIT	XBiotech Inc
2023/05/17	22:22	Edgar (US Regulatory)	Tender Offer Statement by Issuer (sc To-i)	NASDAQ:XBIT	XBiotech Inc
2023/05/17	22:00	GlobeNewswire Inc.	XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares	NASDAQ:XBIT	XBiotech Inc
2023/05/11	04:42	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XBIT	XBiotech Inc
2023/04/29	01:38	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:XBIT	XBiotech Inc
2023/04/29	01:33	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:XBIT	XBiotech Inc
2023/02/15	20:12	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XBIT	XBiotech Inc
2023/02/11	02:22	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:XBIT	XBiotech Inc
2023/02/11	02:21	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:XBIT	XBiotech Inc
2023/02/11	02:21	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:XBIT	XBiotech Inc
2023/01/13	00:29	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:XBIT	XBiotech Inc

검색 관련기사 보기:NASDAQ:XBIT

1 2 3 4 5 6 7 8 9 10 다음 >>

iShares iBonds 2030 Term...

Orange SA 1.375% 20mar2028

Magnetite Mines

Financiere Moncey

MilkyWay Token by SpaceSwap v2

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관